The FDA included quinacrine hydrochloride to its list of bulk drug substances allowed to be used in compounding by outsourcing facilities on April 6. It is the fifth addition and is for oral use only.
The other products on the list are diphenylcyclopropenone, glycolic acid, squaric acid dibutyl ester and trichloroacetic acid, all of which are only for topical use.
In an email alert, the agency said it evaluated 10 others — hydroxyzine HCl, mannitol, methacholine chloride, metoclopramide HCl, nalbuphine HCl, potassium acetate, procainamide HCl, sodium bicarbonate, sodium nitroprusside and verapamil HCl — but those are not on the list "at this time."